Search

Your search keyword '"Jones, Lisa A."' showing total 114 results
Start Over Author "Jones, Lisa A." Publisher wiley
114 results on '"Jones, Lisa A."'

1. Depressive symptoms are associated with clinical outcomes in heart failure with reduced ejection fraction

Author

Sherwood, Andrew, primary, Blumenthal, James A., additional, Mentz, Robert J., additional, Koch, Gary G., additional, Rogers, Joseph G., additional, Chang, Patricia P., additional, Chien, Christopher, additional, Adams, Kirkwood F., additional, Rose‐Jones, Lisa J., additional, Jensen, Brian C., additional, Donahue, Mark, additional, Johnson, Kristy S., additional, and Hinderliter, Alan L., additional

Published
2024
Full Text
View/download PDF

2. Mental health bias in physical care: An integrative review of the literature

Author

Hallyburton, Ann, Allison-Jones, Lisa, Hallyburton, Ann, and Allison-Jones, Lisa

Abstract

What is known on the subject?: Individuals experiencing mental illness make up a significant portion of the world's population. Individuals with mental illness experience higher rates of morbidity and die on average at least a decade earlier than individuals without mental health disorders. What this paper adds to existing knowledge?: Issues of stigma, diagnostic overshadowing, premature closure, inadequate workup, fear and lack of training negatively impact the care of individuals with mental illness. Issues impacting the care of individuals experiencing mental illness cross geographic and care setting boundaries. What are the implications for practice?: Partnerships between physical and mental health practitioners are needed to thoroughly assess and accurately diagnose symptoms experienced by individuals with mental illness. Educational interventions can help prepare practitioners to care for individuals with mental illness. Nurses can better advocate for effective patient care by learning about the phenomenon of diagnostic overshadowing and calling attention to its occurrence. Abstract: Introduction Individuals with mental illness experience significantly higher overall rates of morbidity and mortality than counterparts without mental illness. Misdiagnosis of symptoms emanating from physical illnesses as psychiatric in nature presents one important cause. Aim This integrative review explores research on healthcare professionals' misattribution of physical health symptoms to patients' comorbid psychiatric issues and seeks to identify unifying themes, shared causes, and possible strategies for addressing the issue. Method This review uses Whittemore and Knafl's 2005 integrative review methodology coupled with vetted quality appraisal tools. Results Following a systematic search of allied health, medical, psychological, sociological and general literature, 24 publications employing qualitative, quantitative, mixed and synthesis research methodologies were selected.

Published
2023

9. Lipid intensive drug therapy for sepsis pilot: A Bayesian phase I clinical trial

Author

Guirgis, Faheem W., primary, Black, Lauren Page, additional, DeVos, Elizabeth, additional, Henson, Morgan, additional, Ferreira, Jason, additional, Miller, Taylor, additional, Rosenthal, Martin, additional, Leeuwenburgh, Christiaan, additional, Kalynych, Colleen, additional, Moldawer, Lyle, additional, Jones, Lisa, additional, Crandall, Marie, additional, Reddy, Srinivasa T., additional, Gao, Hanzhi, additional, Wu, Sam, additional, and Moore, Frederick, additional

Published
2020
Full Text
View/download PDF

11. Genetic comorbidity between major depression and cardio‐metabolic traits, stratified by age at onset of major depression

Author

Hagenaars, Saskia P., primary, Coleman, Jonathan R. I., additional, Choi, Shing Wan, additional, Gaspar, Héléna, additional, Adams, Mark J., additional, Howard, David M., additional, Hodgson, Karen, additional, Traylor, Matthew, additional, Air, Tracy M., additional, Andlauer, Till F. M., additional, Arolt, Volker, additional, Baune, Bernhard T., additional, Binder, Elisabeth B., additional, Blackwood, Douglas H. R., additional, Boomsma, Dorret I., additional, Campbell, Archie, additional, Cearns, Micah, additional, Czamara, Darina, additional, Dannlowski, Udo, additional, Domschke, Katharina, additional, Geus, Eco J. C., additional, Hamilton, Steven P., additional, Hayward, Caroline, additional, Hickie, Ian B., additional, Hottenga, Jouke Jan, additional, Ising, Marcus, additional, Jones, Ian, additional, Jones, Lisa, additional, Kutalik, Zoltan, additional, Lucae, Susanne, additional, Martin, Nicholas G., additional, Milaneschi, Yuri, additional, Mueller‐Myhsok, Bertram, additional, Owen, Michael J., additional, Padmanabhan, Sandosh, additional, Penninx, Brenda W. J. H., additional, Pistis, Giorgio, additional, Porteous, David J., additional, Preisig, Martin, additional, Ripke, Stephan, additional, Shyn, Stanley I., additional, Sullivan, Patrick F., additional, Whitfield, John B., additional, Wray, Naomi R., additional, McIntosh, Andrew M., additional, Deary, Ian J., additional, Breen, Gerome, additional, and Lewis, Cathryn M., additional

Published
2020
Full Text
View/download PDF

16. Pharmacological interventions for prevention and treatment of upper gastrointestinal bleeding in newborn infants

Author

Green, Daniel Stephen, Abdel‐Latif, Mohamed E, Jones, Lisa J, Lui, Kei, and Osborn, David A

Subjects
Histamine H2 Antagonists, Enterocolitis, Necrotizing, Sucralfate, Infant, Newborn, Humans, Proton Pump Inhibitors, Pharmacology (medical), Anti-Ulcer Agents, Gastrointestinal Hemorrhage, Randomized Controlled Trials as Topic
Abstract

BACKGROUND: Upper gastrointestinal bleeding is typically a mild, self‐limiting condition that can affect both preterm and term neonates, although it can be severe particularly when associated with co‐morbidities. Pharmacological interventions with a proton pump inhibitor (PPI), H2 receptor antagonist (H2RA), antacid, bismuth and sucralfate may have effects on both the prevention and treatment of upper gastrointestinal bleeding in infants. OBJECTIVES: To assess how different pharmacological interventions (PPIs, H2RAs, antacids, sucralfate or bismuth salts) administered to preterm and term neonates for the prevention or treatment of upper gastrointestinal bleeding to reduce morbidity and mortality compare with placebo or no treatment, supportive care, or each other. SEARCH METHODS: We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2018, Issue 6), MEDLINE via PubMed (1966 to 12 July 2018), Embase (1980 to 12 July 2018), and CINAHL (1982 to 12 July 2018). We also searched clinical trial databases, conference proceedings, the reference lists of retrieved articles for randomised controlled trials and quasi‐randomised trials, and online for Chinese literature articles. SELECTION CRITERIA: We selected randomised, quasi‐randomised and cluster‐randomised trials involving preterm and term neonates. Trials were included if they used a proton pump inhibitor, H2 receptor antagonist, antacid, sucralfate or bismuth either for the prevention or treatment of upper gastrointestinal bleeding. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed the eligibility of studies for inclusion, extracted data and assessed methodological quality. We conducted meta‐analysis using a fixed‐effect model. We used the GRADE approach to assess quality of evidence. MAIN RESULTS: Eleven studies with 818 infants met the criteria for inclusion in this review. Four trials with 329 infants assessed the use of an H2 receptor antagonist for prevention of upper gastrointestinal bleeding in high‐risk newborn infants. Meta‐analysis of these four trials identified a reduction in any upper gastrointestinal bleeding when using an H2 receptor antagonist (typical risk ratio (RR) 0.36, 95% confidence interval (CI) 0.22 to 0.58; typical risk difference (RD) −0.20, 95% CI −0.28 to −0.11; number needed to treat for an additional beneficial outcome (NNTB) 5, 95% CI 4 to 9). The quality of evidence was moderate. A single trial with 53 infants assessing prevention of upper gastrointestinal bleeding reported no difference in mortality in infants assigned H2 receptor antagonist versus no treatment; however the quality of evidence was very low. Seven trials with 489 infants assessed an inhibitor of gastric acid (H2 receptor antagonist or proton pump inhibitor) for treatment of gastrointestinal bleeding in newborn infants. Meta‐analysis of two trials (131 infants) showed no difference in mortality from use of a H2 receptor antagonist compared to no treatment. The quality of evidence was low. Meta‐analysis of two trials (104 infants) showed a reduction in duration of upper gastrointestinal bleeding from use of an inhibitor of gastric acid compared to no treatment (mean difference −1.06 days, 95% CI −1.28 to −0.84). The quality of evidence was very low. Meta‐analysis of six trials (451 infants) showed a reduction in continued upper gastrointestinal bleeding from use of any inhibitor of gastric acid compared to no treatment (typical RR 0.36, 95% CI 0.26 to 0.49; typical RD −0.26, 95% CI −0.33, −0.19; NNTB 4, 95% CI 3 to 5). The quality of evidence was low. There were no significant subgroup differences in duration of upper gastrointestinal bleeding or of continued upper gastrointestinal bleeding according to type of inhibitor of gastric acid. A single trial (38 infants) reported no difference in anaemia requiring blood transfusion from use of a H2 receptor antagonist compared to no treatment. Although no serious adverse events were reported from the use of a H2 receptor antagonist or proton pump inhibitor, some neonatal morbidities — including necrotising enterocolitis, ventilator‐associated pneumonia, duration of ventilation and respiratory support, and duration of hospital stay — were not reported. Long‐term outcome was not reported. AUTHORS' CONCLUSIONS: There is moderate‐quality evidence that use of an H2 receptor antagonist reduces the risk of gastrointestinal bleeding in newborn infants at high risk of gastrointestinal bleeding. There is low‐quality evidence that use of an inhibitor of gastric acid (H2 receptor antagonist or proton pump inhibitor) reduces the duration of upper gastrointestinal bleeding and the incidence of continued gastric bleeding in newborn infants with gastrointestinal bleeding. However, there is no evidence that use of an inhibitor of gastric acid in newborn infants affects mortality or the need for blood transfusion. As no study reported the incidence of necrotising enterocolitis, ventilator‐ or hospital‐associated pneumonia, sepsis, or long‐term outcome, the safety of inhibitors of gastric acid secretion is unclear.

Published
2019

17. A data-driven investigation of relationships between bipolar psychotic symptoms and schizophrenia genome-wide significant genetic loci

Author

Leonenko, Ganna, Di Florio, Arianna, Allardyce, Judith, Forty, Liz, Knott, Sarah, Jones, Lisa, Gordon-Smith, Katherine, Owen, Michael J., Jones, Ian, Walters, James, Craddock, Nick, O'Donovan, Michael C., and Escott-Price, Valentina

Subjects
schizophrenia, RC0321, sparse canonical correlation analysis, BF, OPCRIT, psychosis, bipolar
Abstract

The etiologies of bipolar disorder (BD) and schizophrenia include a large number of common risk alleles, many of which are shared across the disorders. BD is clinically heterogeneous and it has been postulated that the pattern of symptoms is in part determined by the particular risk alleles carried, and in particular, that risk alleles also confer liability to schizophrenia influence psychotic symptoms in those with BD. To investigate links between psychotic symptoms in BD and schizophrenia risk alleles we employed a data-driven approach in a genotyped and deeply phenotyped sample of subjects with BD. We used sparse canonical correlation analysis (sCCA) (Witten, Tibshirani, & Hastie,) to analyze 30 psychotic symptoms, assessed with the OPerational CRITeria checklist, and 82 independent genome-wide significant single nucleotide polymorphisms (SNPs) identified by the Schizophrenia Working group of the Psychiatric Genomics Consortium for which we had data in our BD sample (3,903 subjects). As a secondary analysis, we applied sCCA to larger groups of SNPs, and also to groups of symptoms defined according to a published factor analyses of schizophrenia. sCCA analysis based on individual psychotic symptoms revealed a significant association (p =.033), with the largest weights attributed to a variant on chromosome 3 (rs11411529), chr3:180594593, build 37) and delusions of influence, bizarre behavior and grandiose delusions. sCCA analysis using the same set of SNPs supported association with the same SNP and the group of symptoms defined “factor 3” (p =.012). A significant association was also observed to the “factor 3” phenotype group when we included a greater number of SNPs that were less stringently associated with schizophrenia; although other SNPs contributed to the significant multivariate association result, the greatest weight remained assigned to rs11411529. Our results suggest that the canonical correlation is a useful tool to explore phenotype–genotype relationships. To the best of our knowledge, this is the first study to apply this approach to complex, polygenic psychiatric traits. The sparse canonical correlation approach offers the potential to include a larger number of fine-grained systematic descriptors, and to include genetic markers associated with other disorders that are genetically correlated with BD.

Published
2018

20. Agitated depression in bipolar disorder

Author

Serra, Francesca, primary, Gordon‐Smith, Katherine, additional, Perry, Amy, additional, Fraser, Christine, additional, Di Florio, Arianna, additional, Craddock, Nick, additional, Jones, Ian, additional, and Jones, Lisa, additional

Published
2019
Full Text
View/download PDF

25. Individual and monitoring centre influences upon anticoagulation control of AF patients on warfarin: A longitudinal multi-centre UK-based study

Author

Abohelaika, Salah, primary, Wynne, Hilary, additional, Avery, Peter, additional, Robinson, Brian, additional, Jones, Lisa, additional, Tait, Campbell, additional, Dickinson, Bradley, additional, Salisbury, Julie, additional, Nightingale, Joanna, additional, Green, Louise, additional, and Kamali, Farhad, additional

Published
2018
Full Text
View/download PDF

30. Genome-wide significant locus for Research Diagnostic Criteria Schizoaffective Disorder Bipolar type

Author

Green, Elaine K., primary, Di Florio, Arianna, additional, Forty, Liz, additional, Gordon-Smith, Katherine, additional, Grozeva, Detelina, additional, Fraser, Christine, additional, Richards, Alexander L., additional, Moran, Jennifer L., additional, Purcell, Shaun, additional, Sklar, Pamela, additional, Kirov, George, additional, Owen, Michael J., additional, O'Donovan, Michael C., additional, Craddock, Nick, additional, Jones, Lisa, additional, and Jones, Ian R., additional

Published
2017
Full Text
View/download PDF

40. Characterisation of the genomic landscape of CRLF2‐rearranged acute lymphoblastic leukemia

Author

Russell, Lisa J., primary, Jones, Lisa, additional, Enshaei, Amir, additional, Tonin, Stefano, additional, Ryan, Sarra L., additional, Eswaran, Jeyanthy, additional, Nakjang, Sirintra, additional, Papaemmanuil, Elli, additional, Tubio, Jose M. C., additional, Fielding, Adele K., additional, Vora, Ajay, additional, Campbell, Peter J., additional, Moorman, Anthony V., additional, and Harrison, Christine J., additional

Published
2017
Full Text
View/download PDF

41. Pulmonary hypertension

Author

Rose‐Jones, Lisa J., primary, Fox, Daniel, additional, McLaughlin, David P., additional, and Stouffer, George A., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results